» Articles » PMID: 12059906

Heterogeneity in the Granulomatous Response to Mycobacterial Infection in Patients with Defined Genetic Mutations in the Interleukin 12-dependent Interferon-gamma Production Pathway

Overview
Publisher Wiley
Specialty Pathology
Date 2002 Jun 13
PMID 12059906
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with genetic lesions in the Type-1 cytokine/cytokine receptor pathway exhibit a selective susceptibility to severe infections with poorly pathogenic mycobacteria and non-typhi salmonella spp. These experiments of nature demonstrate that IL-12-dependent IFNgamma production is critical for granuloma formation and therefore host immunity against such pathogens. The essential role of granuloma formation for protective immunity to these organisms is emphasized by the differing granuloma forming capabilities and resultant clinical sequelae observed in these patients which seems to reflect their ability to produce or respond to IFNgamma (Fig. 9). At one pole of this spectrum, represented by the complete IFNgammaR1/2 deficient patients, there is a complete absence of mature granuloma formation, whereas with the less severe mutations (i.e. partial IFNgammaR1/2, complete IL-12p40 and complete IL-12Rbeta1 deficiency), granuloma formation is very heterogenous with wide variations in composition being observed. This suggests that in the latter individuals, who produce partial but suboptimal IFNgamma responses, other influences, including pathogen virulence and host genotype may also affect the type and scale of the cellular response elicited.

Citing Articles

Virulence Mechanisms of : Current Knowledge and Implications for Vaccine Design.

Ferrell K, Johansen M, Triccas J, Counoupas C Front Microbiol. 2022; 13:842017.

PMID: 35308378 PMC: 8928063. DOI: 10.3389/fmicb.2022.842017.


Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease.

Singh K, Rathore U, Rai M, Behera M, Jain N, Ora M J Inflamm Res. 2022; 15:1521-1541.

PMID: 35256852 PMC: 8898181. DOI: 10.2147/JIR.S355881.


Beyond Antibiotics: Photo/Sonodynamic Approaches for Bacterial Theranostics.

Pang X, Li D, Zhu J, Cheng J, Liu G Nanomicro Lett. 2021; 12(1):144.

PMID: 34138184 PMC: 7770670. DOI: 10.1007/s40820-020-00485-3.


A novel ATM mutation associated with elevated atypical lymphocyte populations, hyper-IgM, and cutaneous granulomas.

Minto H, Mensah K, Reynolds P, Meffre E, Rubtsova K, Gelfand E Clin Immunol. 2019; 200:55-63.

PMID: 30639167 PMC: 7027322. DOI: 10.1016/j.clim.2019.01.002.


Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models.

Obregon-Henao A, Arnett K, Henao-Tamayo M, Massoudi L, Creissen E, Andries K Antimicrob Agents Chemother. 2015; 59(11):6904-12.

PMID: 26303795 PMC: 4604395. DOI: 10.1128/AAC.00459-15.


References
1.
Holland S, Eisenstein E, Kuhns D, Turner M, Fleisher T, Strober W . Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med. 1994; 330(19):1348-55. DOI: 10.1056/NEJM199405123301904. View

2.
Dorman S, Holland S . Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 2000; 11(4):321-33. DOI: 10.1016/s1359-6101(00)00010-1. View

3.
Cooper A, Magram J, Ferrante J, Orme I . Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med. 1997; 186(1):39-45. PMC: 2198958. DOI: 10.1084/jem.186.1.39. View

4.
Kang T, Chae G . Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol. 2001; 31(1):53-8. DOI: 10.1111/j.1574-695X.2001.tb01586.x. View

5.
McNutt N . The S100 family of multipurpose calcium-binding proteins. J Cutan Pathol. 1998; 25(10):521-9. DOI: 10.1111/j.1600-0560.1998.tb01735.x. View